icobrain dm

icometrix
icobrain dm aims to assists healthcare professionals in achieving a diagnosis of dementia and Alzheimer’s disease (AD).

icobrain dm uncovers abnormality patterns by:
- Reporting sensitive brain volumetrics to allow the early detection of AD and other diseases causing dementia (whole brain and ventricular volumes and ratio).
- Quantifying and tracking cortical brain volumes and asymmetries to help with the differential diagnosis of the most common dementia types (frontal, parietal, temporal, occipital, and hippocampal cortex)
- Comparing volumes and volume changes to an age-and sex-matched normative reference population.
- Visualizing abnormality patterns in an intuitive volume signature.
Information source: Vendor
Last updated: Jan. 24, 2024

General Information

General
Product name icobrain dm
Company icometrix
Subspeciality Neuro
Modality MR, CT
Disease targeted Dementia
Key-features Brain region quantification, report generation, brain volume changes
Suggested use During: perception aid (prompting all abnormalities/results/heatmaps), report suggestion

Technical Specifications

Data characteristics
Population MCI, dementia, Alzheimer's, FTD, DLB, ...
Input For MRI: 3D T1 weighted image
Input format DICOM
Output Color-coded segmentation overlays, concise reports with reference statistics, pre-populated radiological reporting template
Output format DICOM
Technology
Integration Integration in standard reading environment (PACS), Integration RIS (Radiological Information System), Integration via AI marketplace or distribution platform
Deployment Cloud-based
Trigger for analysis Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time > 10 minutes

Regulatory

Certification
CE
Certified, Class I , MDD
FDA 510(k) cleared , Class II
Intended Use Statements
Intended use (according to CE) icobrain ct is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures from a set of computed tomography (CT) images. This software is intended to automate the current manual process of identifying, labeling and quantifying the volume of segmentable brain structures identified on CT images. The software can also be used to perform image processing, analysis, and communication of computed tomography perfusion (CTP) scans of the brain. icobrain mr is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures from a set of MR images. This software is intended to automate the current manual process of identifying, labeling and quantifying the volume of segmentable brain structures identified on MR images. icobrain mr consists of two distinct image processing pipelines: icobrain mr cross and icobrain mr long. icobrain mr cross is intended to provide volumes from images acquired at a single timepoint. icobrain mr long is intended to provide changes in volumes between two images that were acquired on the same scanner, with the same image acquisition protocol and with same contrast at two different timepoints. The results of icobrain mr cross cannot be compared with the results of icobrain mr long.

Market

Market presence
On market since 2018
Distribution channels Blackford, GE Edison marketplace, Nuance PIN, Calantic
Countries present (clinical, non-research use) 23
Paying clinical customers (institutes) >100
Research/test users (institutes) >300
Pricing
Pricing model Subscription
Based on Number of analyses

Evidence

Evidence
Peer reviewed papers on performance

  • Towards validation in clinical routine: a comparative analysis of visual MTA ratings versus the automated ratio between inferior lateral ventricle and hippocampal volumes in Alzheimer’s disease diagnosis (read)

  • Combining semi-quantitative rating and automated brain volumetry in MRI evaluation of patients with probable behavioural variant of fronto-temporal dementia: an added value for clinical practise? (read)

  • Automated MRI volumetry as a diagnostic tool for Alzheimer's disease: Validation of icobrain dm (read)

  • Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer's Disease in a Clinical Setting: A REMEMBER Study (read)

Non-peer reviewed papers on performance
Other relevant papers